Research archive for SYK

Stryker, the medical devices business, reported numbers last week, and guided for the year ahead -> 2015 Results and 2016 Outlook. As you can see at face value, the company had a tough year, still, it was definitely acceptable. Total sales for the year, net sales, nearly topped the 10 billion mark, 9.9 billion Dollars, net earnings of 1.4 billion Dollars was achieved. On an earnings per share basis the company chugged out 3.78 Dollars, at 99.30 Dollars where the stock closed last night it trades on a historical multiple of 26.2 times, not cheap by any stretch of the imagination.

In amongst the excitement of Thursday evenings reporting came that of Stryker, the Third Quarter Highlights looked a little more like the Samoa checklist of their World Cup highlights. Some, not enough to please the pundits. The stock sank over four percent Friday on a day that stocks were on balance going a lot higher. After the move Friday the stock is trading flat for the year. Why the sudden slowdown in revenues, both orthopaedics and the MedSurg divisions were flat? Partly the Dollar, as you can see in constant currencies sales would have in those two divisions been around 5 percent higher year on year. The neurotechnology and spine division area nearly 10 percent in constant currency terms, 5 percent in Dollar terms. That division sadly only represents 20 percent of group revenues, the balance spread almost evening between the two aforementioned ones.

Stryker reported second quarter numbers on Thursday evening, raising their guidance for the year on an improved outlook. To borrow a line from Jim Cramer, there is always someone making money in some market. You can try, yet you will never suppress human ingenuity. We have seen technological advances in the fields of medicine, and that continues to be the case with improved hardware and software across all fields. They augment each other well, the science of medicine is more receptive to these changes. As per their website, Stryker "offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes."

Stryker reported operating results for the first quarter of 2015, follow the link for all the numbers. The company is a global leader in medical equipment, better known for their selling of knee and hip replacements, as well as a whole host of other devices. Everything from a surgical drill, a saw, smart meters and high tech surgical equipment (screens and the like), to innovations like eliminating surgical smoke (important) to fluid disposal. The Neptune 2 is a fluid disposal product.

Yesterday we received 4th quarter and full year results from one of our recommend healthcare stocks in the US namely Stryker. I've taken a screen grab from the presentation which summarises sales growth amongst the business's divisions. MedSurg is the devices and equipment division, the other 2 are self explanatory.

A couple of days back we received results from one of our recommended healthcare stocks in the US, Stryker. These results were for the 3rd quarter of 2014. This table does many jobs for me. It shows you sales growth, geographic spread and the sales mix between their three main categories, Reconstructive, Medsurg and Neurotechnology and Spine.

Last week we received second quarter results from Stryker. We have written about them before but here is a brief reminder of what this $30bn market cap company does.

Two days ago we received more M&A news in the healthcare sector, this time involving one of Vestact's recommended stocks. Stryker were rumoured to be interested in buying UK company Smith & Nephew. Before we go into the details lets just look at the 2 companies quick.

One of our favourite sectors is the healthcare industry. As global wealth rises so should the amount spent on healthcare, the one thing that can make us live longer and more comfortable. Added to this trend are the ageing baby boomers, who are getting to the age where they require more healthcare.